Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, has published a company update presentation designed to complement remarks that will be provided by management at 3:00 p.m. PT (6:00 p.m. ET) today, Jan. 9, 2023, during the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation provides an overview of the Company’s recent performance and achievements, and offers insight into future goals and catalysts for 2023 and beyond.
The presentation is available on the Investor Relations page of the Bausch + Lomb website at: https://ir.bausch.com/investors/events-presentations. A live webcast and audio archive of the event will also be available on the Investor Relations page of the Company’s web site.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.
Last Trade: | US$14.53 |
Daily Change: | 0.09 0.62 |
Daily Volume: | 168,592 |
Market Cap: | US$5.140B |
August 18, 2025 July 30, 2025 July 29, 2025 June 04, 2025 May 21, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load